ArticleKidney international reports2022

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death.

Argiris Asderakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.